Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial
By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Danegaptide could be an oral therapy for patients with moderate to severe nonproliferative diabetic retinopathy. The treatment was well…